Inventage Lab Inc
389470
Company Profile
Business description
Inventage Lab Inc operates medical technology development businesses. The company engages in the development of an Drug Delivery System (DDS). It has developed Laminar FluiDigm, a microfluidics-based novel platform technology that builds the foundation for IVL- DrugFluidic and IVL-GeneFluidic, which are specific platform technologies used for developing and manufacturing long-acting injectables and gene-delivery therapeutics.
Contact
24, 101, 601, 612, Duncheon-daero 388beon-gil
Jungwon-gu, Sangdaewon-dong, Urim Lions Valley 3cha
Gyeonggi-do
Seongnam-si13403
KORT: +82 316080514
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
69
Stocks News & Analysis
stocks
Lower production and higher prices for ASX hydrocarbon play
Improving pricing offsets severe weather impact on sales volumes.
stocks
Alphabet returns on AI investments accelerating
AI propels business across aegments, cloud is grightest; Increasing our fair value.
stocks
We lift our fair value estimate for this ASX energy play
Strong oil and LNG prices are a major win, though we don’t think they will stay high in the long term.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,888.90 | 18.40 | 0.21% |
| CAC 40 | 8,072.13 | 31.96 | -0.39% |
| DAX 40 | 23,954.56 | 63.70 | -0.27% |
| Dow JONES (US) | 48,861.81 | 280.12 | -0.57% |
| FTSE 100 | 10,213.11 | 119.68 | -1.16% |
| HKSE | 25,787.06 | 324.78 | -1.24% |
| NASDAQ | 24,673.24 | 9.44 | 0.04% |
| Nikkei 225 | 59,204.20 | 713.26 | -1.19% |
| NZX 50 Index | 12,845.05 | 74.75 | 0.59% |
| S&P 500 | 7,135.95 | 2.85 | -0.04% |
| S&P/ASX 200 | 8,664.10 | 23.90 | 0.28% |
| SSE Composite Index | 4,111.02 | 3.50 | 0.09% |